The Bridge the Gap – SYNGAP Corporate Alliance is a coalition of rare disease industry stakeholders focused on advancement in neurological disorders centered on and around SYNGAP1 and related overlapping disorders. The committed collaboration between industry and our patient community will improve and expedite access to effective therapies for SYNGAP1 and overlapping genetic related conditions.
Membership is open to pharmaceutical and biotech companies, industry and academia that want to support patient education, community and capacity building and improved process to accelerate to treatments and research collaborations.
The organizations and alliances Bridge the Gap – SYNGAP Education and Research Foundation partners with having a patient focus, community-centered approach and like-minded vision for the future.
- To maintain communication in the current research surrounding neurological disorders, both in development and neurodegenerative medicine surrounding SYNGAP1.
- To develop and disseminate consensus policy positions to address identified policy barriers at both the federal and legislative levels.
- Promote the creation of new clinical and non-clinical resources to be made available to the undiagnosed community in the neurological space.
- Facilitate public engagement between medical and policy experts (and between experts and patients) to discuss issues pertinent to the undiagnosed rare community. We hope that you accept our invitation to create future innovation and progress in the neurological landscape of SYNGAP1 and its related disorders.
For More Information: Call (240) 347-0302 or email email@example.com